Assessment of two external telemetry systems (PhysioJacket™ and JET™) in beagle dogs with telemetry implants

Journal of Pharmacological and Toxicological Methods

Volumn 60, Issue 1, 2009, Pages 58-68

  Chui, Ray W ^a   Fosdick, Abigail ^a   Conner, Ra'Shun ^a   Jiang, Jian ^a   Bruenner, Bernd A ^a   Vargas, Hugo M ^a  

^a AMGEN INC   (United States)

Author keywords

Beagle dogs; E 4031; External telemetry; Implants; Jacket telemetry; JET; Method; Pattern recognition; PhysioJacket; QT interval

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; WATER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR SYSTEM; COMPUTER PROGRAM; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG EXPOSURE; ELECTROCARDIOGRAM; FEMALE; HEART RATE VARIABILITY; IMPLANT; MAXIMUM PLASMA CONCENTRATION; NON INVASIVE PROCEDURE; NONHUMAN; PR INTERVAL; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; TELEMETRY;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; EQUIPMENT AND SUPPLIES; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HEART RATE; MODELS, ANIMAL; PIPERIDINES; PYRIDINES; TELEMETRY;

ANIMALIA; CANIS FAMILIARIS;

EID: 68549134977     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2009.04.196     Document Type: Article

References (24)

1. Ando K., Hombo T., Kanno A., Ikeda H., Imaizumi M., Shimizu N., et al. QT PRODACT: In vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. Journal of Pharmacological Sciences 99 (2005) 487-500
2. Arrigoni C., and Crivori P. Assessment of QT liabilities in drug development. Cell Biology and Toxicology 23 (2007) 1-13
3. Chaves A.A., Zingaro G.J., Yordy M.A., Bustard K.A., O'sullivan S., Galijatovic-Idrizbegovic A., et al. A highly sensitive canine telemetry model for detection of QT interval prolongation: Studies with moxifloxacin, haloperidol and mk-499. Journal of Pharmacological and Toxicological Methods 56 (2007) 103-114
4. Chen X., Cass J.D., Bradley J.A., Dahm C.M., Sun Z., Kadyszewski E., et al. Qt prolongation and proarrhythmia by moxifloxacin: Concordance of preclinical models in relation to clinical outcome. British Journal of Pharmacology 146 (2005) 792-799
5. Fermini B., and Fossa A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Reviews 2 (2003) 439-447
6. Festing M.F.W., and Lovell D.P. Reducing the use of laboratory animals in toxicology research and testing by better experimental design. Journal of the Royal Statistical Society, Series B 58 (1996) 127-140
7. Hamlin R.L. How many ECG leads are required for in vivo studies in safety pharmacology?. Journal of Pharmacological and Toxicological Methods 57 (2008) 161-168
8. Hayashi S., Kii Y., Tabo M., Fukuda H., Itoh T., Shimosato T., et al. QT PRODACT: A multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles. Journal of Pharmacological Sciences 99 (2005) 423-437
9. Lin Y.L., and Kung M.F. Magnitude of QT prolongation associated with a higher risk of torsades de pointes. Pharmacoepidemiology and Drug Safety 18 3 (2009) 235-239
10. Luft J., and Bode G. Integration of safety pharmacology endpoints into toxicology studies. Fundamental & Clinical Pharmacology 16 (2002) 91-103
11. Miyazaki H., Watanabe H., Kitayama T., Nishida M., Nishi Y., Sekiya K., et al. QT PRODACT: Sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation. Journal of Pharmacological Sciences 99 (2005) 523-529
12. Omata T., Kasai C., Hashimoto M., Hombo T., and Yamamoto K. QT PRODACT: Comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. Journal of Pharmacological Sciences 99 (2005) 531-541
13. Raunig D., Depasquale M.J., Huang C.H., Winslow R., and Fossa A.A. Statistical analysis of QT interval as a function of changes in RR interval in the conscious dog. Journal of Pharmacological and Toxicological Methods 46 (2001) 1-11
14. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., Mackenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 58 (2003) 32-45
15. Roden D.M. Drug-induced prolongation of the QT interval. The New England Journal of Medicine 350 (2004) 1013-1022
16. Sasaki H., Shimizu N., Suganami H., and Yamamoto K. QT PRODACT: Inter-facility variability in electrocardiographic and hemodynamic parameters in conscious dogs and monkeys. Journal of Pharmacological Sciences 99 (2005) 513-522
17. Schmelting, B., Niehoff, M., Egner, B., Korte, S. H., & Weinbauer, G. F. (in press). High definition oscillometry: A novel technique for non-invasive blood pressure monitoring in the cynomolgus monkey (Macaca fascicularis). Journal of Medical Primatology, doi:10.1111/j.1600-26894.2009.00344.
18. Soloviev M.V., Hamlin R.L., Barrett R.M., Chengelis C.P., and Schaefer G.J. Different species require different correction factors for the QT interval. Cardiovascular Toxicology 6 (2006) 145-157
19. Sugiyama A. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. British Journal of Pharmacology 154 (2008) 1528-1537
20. Tashibu H., Miyazaki H., Aoki K., Akie Y., and Yamamoto K. QT PRODACT: In vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals. Journal of Pharmacological Sciences 99 (2005) 473-486
21. Tattersall M.L., Dymond M., Hammond T., and Valentin J.P. Correction of QT values to allow for increases in heart rate in conscious beagle dogs in toxicology assessment. Journal of Pharmacological and Toxicological Methods 53 (2006) 11-19
22. Toyoshima S., Kanno A., Kitayama T., Sekiya K., Nakai K., Haruna M., et al. QT PRODACT: In vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. Journal of Pharmacological Sciences 99 (2005) 459-471
23. Van De Water A., Verheyen J., Xhonneux R., and Reneman R.S. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. Journal of Pharmacological Methods 22 (1989) 207-217
24. Vargas H.M., Bass A.S., Breidenbach A., Feldman H.S., Gintant G.A., Harmer A.R., et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. Journal of Pharmacological and Toxicological Methods 58 (2008) 72-76